A Phase 1 Study of the Safety and Tolerability of CTX-10726
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Cynthia Sirard, MD
Compass Therapeutics
Study Director
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
5 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Dana Farber Cancer Institute
Boston, Massachusetts, United States
Haeseong Park, MDNot, yet, recruiting - Nebraska Cancer Specialists
Omaha, Nebraska, United States
Ralph Hauke, MDRecruiting - Start New York
Lake Success, New York, United States
Geraldine O'Sullivan Coyne, MD, PhDRecruiting - Prisma Health Cancer Institute
Greenville, South Carolina, United States
Jeff Edenfield, MDRecruiting - Scri Oncology Partners
Nashville, Tennessee, United States
Meredith Pelster, MDRecruiting
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 28 May 2026
- Primary completion
- 1 Apr 2028
- Completion
- 1 Nov 2028
- Last update posted
- 5 Jun 2026
- Registered enrollment
- 70
- Registry id
- NCT07419841
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.